Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 10/07/2025 pm IST			5-day change	1st Jan Change
455.55 ^DKK	+2.82%		+3.18%	-27.02%

10/07	Mining, healthcare prop up European shares; US-EU trade talks in focus	RE
09/07	Major deals involving U.S. drugmakers and biotechs over the past decade	RE

NOVO NORDISK : Acknowledging the intensifying competition

Published on 06/06/2025 at 21:10

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

Mining, healthcare prop up European shares; US-EU trade talks in focus	10/07	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	09/07	RE
European shares close at four-week high on banks boost; US trade talks in focus	09/07	RE
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update	09/07	DJ
NOVO NORDISK : Deutsche Bank remains its Buy rating	09/07	ZD
Europe rises despite new US tariff mayhem	09/07	AN
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	08/07	MT
European shares rise on energy, healthcare boost; tariff uncertainty lingers	08/07	RE
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval	08/07	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Novo Nordisk Seeks EU Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk Seeks EU Approval for Higher Dose of Weight-loss Drug Wegovy	08/07	MT
Novo Nordisk Seeks Approval for Higher Dose of Wegovy	08/07	FW
Novo Nordisk Seeks European Medicines Agency Approval for New, Higher Dose of Wegovy	08/07	MT
Novo Nordisk submits new Wegovy dose to the European Medicines Agency for approval	08/07	RE
Novo Nordisk submits application to EMA for approval of higher dose of Wegovy	08/07	RE
WeightWatchers names new medical chief, plans to offer menopause therapy and support	08/07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
Italy set to speed through $2.3 billion Novo Nordisk investment	07/07	RE
The importance of being constantly changing…	07/07
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
Demand for obesity drugs shoots up in India as Lilly, Novo vie for market share	07/07	RE
European shares fall as banks, mining stocks losses weigh	04/07	RE
Jyske Bank Lowers Novo Nordisk Price Target to 700 Danish Kroner, Reiterates Buy - BN	04/07	FW

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release

More about the company